Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...

AstraZeneca has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for ...

The UK experienced a notable increase in advanced therapy clinical trials in 2024, reaching 187 ongoing trials. This marks a ...

The European Commission (EC) has approved the marketing authorisation for LAZCLUZE (lazertinib) in combination with RYBREVANT ...

This initiative, funded by the Innovative Health Initiative Joint Undertaking (IHI JU) with over EUR 38 million, aims to ...

AlzeCure Pharma AB announced that its abstract on NeuroRestore ACD856 has been accepted for presentation at the AD/PD 2025 ...

Tris Pharma, Inc. has announced positive results from its ALLEVIATE-1 phase 3 clinical trial evaluating cebranopadol for ...